HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

High Level of Serum Soluble Interleukin-2 Receptor at Transplantation Predicts Poor Outcome of Allogeneic Stem Cell Transplantation for Adult T Cell Leukemia

Files in This Item:
Biol Blood Marrow Transplant_20(6)_801-805.pdf413.8 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: High Level of Serum Soluble Interleukin-2 Receptor at Transplantation Predicts Poor Outcome of Allogeneic Stem Cell Transplantation for Adult T Cell Leukemia
Authors: Shigematsu, Akio Browse this author
Kobayashi, Naoki Browse this author
Yasui, Hiroshi Browse this author
Shindo, Motohiro Browse this author
Kakinoki, Yasutaka Browse this author
Koda, Kyuhei Browse this author
Iyama, Satoshi Browse this author
Kuroda, Hiroyuki Browse this author
Tsutsumi, Yutaka Browse this author
Imamura, Masahiro Browse this author →KAKEN DB
Teshima, Takanori Browse this author →KAKEN DB
Keywords: Adult T cell leukemia
Allogeneic stem cell transplantation
Region-wide study
Soluble interleukin-2 receptor
Prognostic factor
Issue Date: Jun-2014
Publisher: Elsevier
Journal Title: Biology of Blood and Marrow Transplantation
Volume: 20
Issue: 6
Start Page: 801
End Page: 805
Publisher DOI: 10.1016/j.bbmt.2014.02.014
PMID: 24565990
Abstract: The prognosis for adult T cell leukemia/lymphoma (ATL) is very poor, and only allogeneic hematopoietic stem cell transplantation (allo-SCT) has been considered to be a curative treatment for ATL. In this study, we retrospectively analyzed data for patients who had received allo-SCT for ATL in Hokkaido, the northernmost island of Japan, to determine prognostic factors. Fifty-six patients with a median age of 57 years received allo-SCT. Twenty-eight (50.0%) patients had acute type and 22 (46.4%) had lymphoma type. Twenty-three (41.1%) patients received allo-SCT in complete remission (CR), whereas the others were in non-CR. Seventeen (30.4%) patients received myeloablative conditioning and the others received reduced-intensity conditioning. With a median follow-up period of 48 months (range, 17 to 134 months), 1-year overall survival (OS) and 5-year OS rates were 55.4% and 46.1%, respectively. The survival curve reached a plateau at 22 months after stem cell transplantation (SCT). Male sex, high level of serum soluble interleukin-2 receptor (sIL-2R) at SCT, and non-CR at SCT were determined to be significant risk factors for OS. A high level of sIL-2R at SCT was a risk factor for poor OS in patients with non-CR at SCT by univariate analysis (P = .02), and it remained significant after adjustment by sex (hazard ratio, 2.73 [95% confidence interval, 1.07 to 7.90]). A high level of sIL-2R at SCT was also determined to be a risk factor for disease progression (P = .02). This region-wide study showed encouraging results for survival after allo-SCT for ATL and demonstrated for the first time that a high level of sIL-2R at SCT predicts worse SCT outcome. (C) 2014 American Society for Blood and Marrow Transplantation.
Type: article (author version)
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 重松 明男

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


Feedback - Hokkaido University